公开(公告)号：WO2017035181A1

公开(公告)日：2017-03-02

申请号：PCT/US2016/048278

申请日：2016-08-24

Applicant: GLYCOVAXYN AG ,  JANSSEN PHARMACEUTICALS, INC.

Inventor： POOLMAN, Jan, Theunis ,  JACQUEMYN, Bert ,  ABBANAT, Darren, Robert ,  YON, Patricia, Ibarra ,  HERMANS, Peter, Wilhelmus, Maria ,  KOWARIK, Michael, Thomas ,  WETTER, Michael, Lukas ,  KEMMLER, Stefan, Jochen ,  HAUPTLE, Micha, Andres ,  GAMBILLARA, Veronica ,  MALLY, Manuela

IPC: A61K39/02 ,  C08B37/00 ,  A61K39/00 ,  A61K39/108

CPC classification number: A61K39/0258 ,  A61K47/6415 ,  A61K47/646 ,  A61K2039/545 ,  A61K2039/55583 ,  A61K2039/6037 ,  A61K2039/6087 ,  A61K2039/70 ,  C08B37/0063 ,  Y02A50/474

Abstract: Compositions and methods are described for inducing an immune response against extra-intestinal pathogenic Escherichia coli (ExPEC) to thereby provide immune protection against diseases associated with ExPEC. In particular, compositions and methods are described for using conjugates of E. coli polysaccharide antigens O25B, O1A, O2, and O6A covalently bound to a detoxified exotoxin A of Pseudomonas aeruginosa (EPA) carrier protein as vaccines for the prevention of invasive ExPEC disease caused by ExPEC serotypes O1A, O2, O6A and O25B.

Abstract translation: 描述了诱导针对肠外致病性大肠杆菌（ExPEC）的免疫应答的组合物和方法，从而为与ExPEC相关的疾病提供免疫保护。 具体地，描述了使用与铜绿假单胞菌（EPA）载体蛋白的解毒外毒素A共价结合的大肠杆菌多糖抗原O25B，O1A，O2和O6A的缀合物的组合物和方法作为用于预防引起的侵袭性ExPEC疾病的疫苗 通过ExPEC血清型O1A，O2，O6A和O25B。

公开(公告)号：WO2017031455A1

公开(公告)日：2017-02-23

申请号：PCT/US2016/047854

申请日：2016-08-19

Applicant: UNIVERSITY OF MARYLAND, BALTIMORE

Inventor： ANTALIS, Toni ,  MARTIN, Erik

IPC: A61K38/19 ,  A61K39/02 ,  A61K39/40 ,  C07K14/32

CPC classification number: C07K14/32 ,  A61K38/00 ,  C07K16/38 ,  C07K2319/50

Abstract: Engineered anthrax protective antigen (PrAg) proteins are provided wherein the native furin activation site is replaced by the activation site of a membrane-anchored serine protease. These engineered PrAg proteins retain the ability to bind to cell surface PrAg receptors and be proteolytically activated. The proteins also retain the ability to form membrane pores. These engineered PrAg proteins can be used in methods of inducing pore formation in a cell, methods of inducing translocation of a selected compound or co-factor into a cell, and methods of treating disease, such as cancer, in a subject.

Abstract translation: 提供了工程化的炭疽保护性抗原（PrAg）蛋白质，其中天然弗林蛋白酶活化位点由膜锚定的丝氨酸蛋白酶的活化位点代替。 这些工程化的PrAg蛋白保留结合细胞表面PrAg受体并被蛋白水解激活的能力。 蛋白质还保留形成膜孔的能力。 这些工程化的PrAg蛋白质可以用于诱导细胞中孔形成的方法，诱导选择的化合物或辅因子转移到细胞中的方法，以及治疗受试者中疾病如癌症的方法。

公开(公告)号：WO2017030901A1

公开(公告)日：2017-02-23

申请号：PCT/US2016/046572

申请日：2016-08-11

Applicant: ZOETIS SERVICES LLC ,  THE UNIVERSITY OF MELBOURNE

Inventor： BROWNING, Glenn, Francis ,  MARKHAM, Philip, Francis ,  MARENDA, Marc, Serge ,  WEBER, Fred, H. ,  MAHAN, Suman

IPC: A61K39/02 ,  A01H1/06

CPC classification number: A61K39/0241 ,  A61K2039/522

Abstract: Disclosed herein are Mycoplasma bovis immunogenic compositions useful in raising an immune response in animals against M. bovis . Also disclosed herein are methods for generating a protective response against infections in mammals caused by M. bovis.

Abstract translation: 本文公开了可用于提高动物对牛枝原体免疫应答的支原体牛免疫原性组合物。 本文还公开了产生针对由牛分枝杆菌引起的哺乳动物感染的保护性应答的方法。

公开(公告)号：WO2017017313A1

公开(公告)日：2017-02-02

申请号：PCT/FI2016/050541

申请日：2016-07-22

Applicant: UNIVERSITY OF HELSINKI

Inventor： SALMELA, Heli ,  FREITAK, Dalial

IPC: A61K39/02 ,  A61K39/09 ,  A61K39/00

CPC classification number: A61K39/02 ,  A61K39/09 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/55 ,  A61K2039/60

Abstract: The present invention relates to animals and more specifically to insects. In more details the invention relates to an edible composition or insect artificial diet comprising bacteria, fungi or any fragment or spore thereof for use as a vaccine in preventing a microbial disease or infection in an insect. Still, the present invention relates to preventive methods and different uses relating to said compositions or bacteria, fungi or fragments or spores thereof.

Abstract translation: 本发明涉及动物，更具体地涉及昆虫。 更详细地说，本发明涉及包含细菌，真菌或其任何片段或孢子的可食用组合物或昆虫人造饮食，用作预防昆虫中的微生物疾病或感染的疫苗。 然而，本发明涉及与所述组合物或细菌，真菌或其碎片或孢子有关的预防方法和不同用途。

公开(公告)号：WO2017011338A1

公开(公告)日：2017-01-19

申请号：PCT/US2016/041608

申请日：2016-07-08

Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGE

Inventor： MEKALANOS, John, J. ,  IWASHKIW, Jeremy, Andrew

IPC: A61K39/02 ,  A61K47/48 ,  C07K14/095 ,  C07K19/00 ,  C12P1/04 ,  C12P21/02 ,  C12Q1/26

CPC classification number: A61K39/02 ,  A61K39/092 ,  A61K2039/6031 ,  A61K2039/627 ,  C07K14/095 ,  C07K14/195 ,  C07K19/00 ,  Y02A50/484

Abstract: Disclosed are immunogenic compositions containing a polysaccharide-sortase conjugate. The polysaccharide is an antigen, and the sortase is a carrier protein. The sortase is covalently linked to the polysaccharide antigen by a linker including a sortase recognition sequence. Also disclosed are immunogenic compositions containing a polysaccharide-protein conjugate, the conjugate containing a polysaccharide antigen and a carrier protein. The polysaccharide antigen is covalently linked to the carrier protein by a linker including a sortase recognition sequence and a polyglycine motif present at the N-terminus of the carrier protein. Also disclosed are pharmaceutical compositions containing the immunogenic composition and a pharmaceutically acceptable excipient, methods of making the immunogenic compositions, and methods of generating immune response in a subject using the pharmaceutical composition.

Abstract translation: 公开了含有多糖分选酶缀合物的免疫原性组合物。 多糖是抗原，分选酶是载体蛋白。 分选酶通过包含分选酶识别序列的接头与多糖抗原共价连接。 还公开了含有多糖 - 蛋白质缀合物，含有多糖抗原和载体蛋白的缀合物的免疫原性组合物。 多糖抗原通过包含分离酶识别序列和存在于载体蛋白N末端的聚甘氨酸基序的接头与载体蛋白共价连接。 还公开了含有免疫原性组合物和药学上可接受的赋形剂，制备免疫原性组合物的方法，以及使用该药物组合物在受试者中产生免疫应答的方法的药物组合物。

公开(公告)号：WO2017007852A1

公开(公告)日：2017-01-12

申请号：PCT/US2016/041192

申请日：2016-07-06

Applicant: PROTEIN POTENTIAL, LLC

Inventor： WU, Yun ,  KOPECKO, Dennis J. ,  SIM, B. Kim Lee ,  HOFFMAN, Stephen L.

IPC: A61K39/02 ,  A61K39/112 ,  A61P31/04

CPC classification number: A61K39/0283 ,  A61K39/0275 ,  A61K2039/522 ,  A61K2039/523 ,  A61K2039/543 ,  A61K2039/70 ,  Y02A50/476 ,  Y02A50/482 ,  Y02A50/484

Abstract: Disclosed is the attenuated Salmonella typhi vaccine Ty21a utilized as a vector for Shigella and/or enterotoxogenic E. coli genes stably integrated in the Ty21a chromosome. These genes include a heterologous Shigella sonnei O-antigen biosynthetic gene region that comprises the wzz gene and expresses Shigella sonnei form 1 O-antigen, as well as a heterologous acid resistance biosynthetic gene system comprising a YbaS gene, which enables increased stability of the Ty21a vector at pH 2.5 relative to Ty21a without the integrated acid resistance biosynthetic gene system.

Abstract translation: 公开了减毒的伤寒沙门氏菌疫苗Ty21a用作稳定整合在Ty21a染色体中的志贺氏菌和/或肠毒性大肠杆菌基因的载体。 这些基因包括异源志贺氏杆菌O抗原生物合成基因区，其包含wzz基因并表达1-O-抗原志贺氏菌，以及包含YbaS基因的异源抗酸生物合成基因系统，其能够增强Ty21a的稳定性 载体在相对于Ty21a的pH2.5没有积分的抗酸生物合成基因系统。

公开(公告)号：WO2017006349A1

公开(公告)日：2017-01-12

申请号：PCT/IN2016/050218

申请日：2016-07-04

Applicant: BHARAT BIOTECH INTERNATIONAL LIMITED

Inventor： ELLA, Krishna Murthy ,  KUMAR, Ashawani ,  RAMASWAMY, Venkatesan ,  MURTHY, Voleti Subrahmanya Ramachandra

IPC: A61K39/02 ,  A61K39/095 ,  A61K39/112

CPC classification number: A61K39/095 ,  A61K39/0275 ,  A61K47/24 ,  A61K2039/6037 ,  A61K2039/70 ,  A61P31/04 ,  C12N1/20 ,  C12P19/04 ,  Y02A50/482 ,  Y02A50/484

Abstract: The present invention relates to the field of combined vaccine compositions which are effective against all forms of meningococcal diseases as well as typhoid fever. The vaccine formulations comprising antigens from capsular polysaccharides of Neisseria meningitidis A, Neisseria meningitidis C, Neisseria meningitidis Y, Neisseria meningitidis W135, Neisseria meningitidis X, Salmonella typhi Vi capsular polysaccharide (ViPs) or capsular ViPs conjugated to a carrier protein tetanus toxoid (ViPs-TT). This invention is also related to improved methods, especially the use of an improved feed media and an improved method of downstream processing and industrial purification of capsular polysaccharides. The vaccine is free of any animal component or alcohol and is in absolute compliance with respect to the religious sentiments of various ethnic groups. The composition is highly effective and stable, yet cost- effective and affordable, especially for lower-middle income and low-income countries.

Abstract translation: 本发明涉及对所有形式的脑膜炎球菌疾病以及伤寒都有效的联合疫苗组合物领域。 包含脑膜炎奈瑟球菌A，脑膜炎奈瑟氏球菌C，脑膜炎奈瑟氏球菌Y，脑膜炎奈瑟菌脑膜炎奈瑟氏球菌W135，脑膜炎奈瑟氏球菌X，伤寒沙门氏菌Vi荚膜多糖（ViPs）或与载体蛋白质破伤风类毒素（ViPs- TT）。 本发明还涉及改进的方法，特别是改进的饲料培养基的使用以及荚膜多糖的下游加工和工业纯化的改进方法。 疫苗不含任何动物成分或酒精，绝对符合各族宗教情怀。 组合是高效和稳定的，但成本效益和负担得起的，特别是对于中低收入国家和低收入国家。

公开(公告)号：WO2016205434A1

公开(公告)日：2016-12-22

申请号：PCT/US2016/037728

申请日：2016-06-16

Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED

Inventor： BARBET, Anthony, F. ,  CROSBY, Francy, L.

IPC: A61K39/02 ,  A61K39/39 ,  A61K39/00

CPC classification number: A61K39/0233

Abstract: The invention pertains to the use of VirB10 to immunize a host against an infection by a bacterium having T4SS. The invention provides a vaccine comprising VirB10, a fragment of VirB10, a polynucleotide encoding VirB10 or a polynucleotide encoding a fragment of VirB10 and a pharmaceutically acceptable carrier and/or adjuvant. The invention also provides a method of immunizing a host against an infection caused by a bacterium having T4SS, the method comprising administering to the host a vaccine of the invention. The vaccines and the methods of the invention can be used to immunize against infections caused by bacteria having T4SS in dogs, rabbits, cats, pigs, cattle, sheep, goats, deer, horses, rodents and humans.

Abstract translation: 本发明涉及使用VirB10免疫宿主免受具有T4SS的细菌的感染。 本发明提供了包含VirB10，VirB10的片段，编码VirB10的多核苷酸或编码VirB10片段的多核苷酸和药学上可接受的载体和/或佐剂的疫苗。 本发明还提供了免疫宿主免受由具有T4SS的细菌引起的感染的方法，所述方法包括向宿主施用本发明的疫苗。 本发明的疫苗和方法可用于免疫犬，兔，猫，猪，牛，绵羊，山羊，鹿，马，啮齿动物和人类中具有T4SS的细菌引起的感染。

公开(公告)号：WO2016204644A1

公开(公告)日：2016-12-22

申请号：PCT/RU2015/000379

申请日：2015-06-19

Applicant: ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "ПАНАЦЕЛА ЛАБС"

Inventor： ШМАРОВ, Максим Михайлович ,  КАЛУГИНА, Ирина Алексеевна ,  САМОРУКОВА, Александра Владимировна ,  АЛФЕРОВА, Наталья Сергеевна ,  АТАУЛЛАХАНОВ, Рустам Равшанович ,  ЕРЕМИНА, Наталья Вахитовна ,  КАЗЕЙ, Василий Игоревич

IPC: C12N7/01 ,  C12N7/02 ,  C12N15/63 ,  C12N15/12 ,  C12N15/31 ,  A61P35/00 ,  A61K35/76 ,  A61K31/7088 ,  A61K39/02 ,  C07K14/705

CPC classification number: A61K35/76 ,  A61K31/7088 ,  A61K39/02 ,  C07K14/705 ,  C12N7/02 ,  C12N15/63

Abstract: Изобретение относится к биотехнологии и касается способа производства препарата «Мобилан (M-VM3)». Изобретение оптимизирует стадии производства, повышая его рентабельность, делая оптимальным соотношение время производства/количество полученного препарата/количество средств, затраченных на производство. В частности, в ходе модернизации были разработаны следующие устойчивые параметры производственного процесса: объем партии 1500 флаконов, время на производство -18-22 суток, общий расход питательной среды 44 л, объем вирус-содержащей супензии M-VM3 - 25 л, плотность клеток во время заражения - в диапазоне от 0,8 х 10 6 до 1 х 10 6 кл/мл; время сбора клеток - на третий день (приблизительно 72 ч); температура при заражении - 36°С, множественность заражения - 5-10 БОЕ/кл, итоговая концентрация вирусного конструкта при сборе 8 х 10 8 БОЕ/мл.

Abstract translation: 本发明涉及生物技术并涉及生产药物“Mobilan（M-VM3）”的方法。 本发明改善生产阶段，提高生产效率，实现生产时间，药物产量与生产所需资源量之间的最佳比例。 特别是在现代化进程中，建立了以下稳定的生产参数：批量1500瓶; 生产时间 - 18-22天; 培养基总量需要44升; 含有病毒的M-VM3悬浮液体积为25升; 感染时细胞密度为0.8×106至1×106细胞/ ml; 细胞收获时间 - 第三天（即约72小时后）; 感染时的温度 - 36°C; 多重感染 - 5-10 PFU /细胞; 收获时病毒构建体的总浓度 - 8х108 PFU / ml。

公开(公告)号：WO2016196383A1

公开(公告)日：2016-12-08

申请号：PCT/US2016/034858

申请日：2016-05-27

Applicant: REBER GENETICS CO., LTD. ,  HEALTHBANKS BIOTECH USA INC.

Inventor： CHIEN, Yu-Hsin ,  TSAI, Meng-Ju ,  LAI, Pao-Yen ,  CHOU, Wei-I ,  CHANG, Hsiu-Kang

IPC: A61K39/02 ,  A61K39/10 ,  A61K39/104

CPC classification number: A61K39/12 ,  A61K2039/70 ,  C07K14/005 ,  C07K14/21 ,  C07K2319/04 ,  C07K2319/095 ,  C07K2319/55 ,  C07K2319/74 ,  C12N2750/10022 ,  C12N2750/10034 ,  C12N2770/10022 ,  C12N2770/10034

Abstract: A fusion protein comprising an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain, a translocation peptide, a fusion antigen, an endoplasmic reticulum retention sequence, and optionally a nuclear export signal is disclosed. The fusion antigen comprises a porcine reproductive and respiratory syndrome virus (PRRSV) ORF7 antigen, a PRRSV ORF1b antigen, a PRRSV ORF6 antigen, and a PRRSV ORF5 antigen. The fusion protein is useful for inducing antigen-specific cell-mediated and humoral responses.

Abstract translation: 公开了包含抗原呈递细胞（APC）结合结构域或CD91受体结合结构域，易位肽，融合抗原，内质网保留序列和任选的核导出信号的融合蛋白。 融合抗原包括猪繁殖与呼吸综合征病毒（PRRSV）ORF7抗原，PRRSV ORF1b抗原，PRRSV ORF6抗原和PRRSV ORF5抗原。 融合蛋白可用于诱导抗原特异性细胞介导的和体液应答。